Table 1. B and T cell frequency in prevention model of Rituximab administration.

	Splenocytes		CNS
	WTLM	hCD20Tg	WTLM	hCD20Tg
Total cells	1.21×108	7.60×107(37.2%)	1.50×105	2.00×105(−33.3%)
B cells	3.21×107	1.18×107(63.2%)	2.20×103	1.91×103(13.2%)
CD4+ T cells	2.13×107	1.44×107(32.4%)	3.54×104	1.05×104(70.34%)
CD8+ T cells	1.02×107	7.12×106(30.2%)	1.41×104	3.92×104(−178.0%)

Cells from each organ were pooled from at least three mice per group and counted. Cell counts were then normalized by dividing the total counts by the numbers of mice in each group and then multiplied by the percentage of each cell type as identified by flow cytometry. Total leukocytes were identified by CD45+ events within FSC and SSC gates. B cells were identified using gates for CD19 and B220. T cells were identified by expression of CD3 and either CD4 or CD8. Numbers in parenthesis indicate the percent change in cell counts in the hCD20Tg mice as compared to WTLM controls.